Form 4: Lipella Pharmaceuticals Executive Reports Changes in Beneficial Ownership Following Registration
SEC Form 4 Filing
Jonathan H. Kaufman, a director and officer of Lipella Pharmaceuticals, reported changes in his beneficial ownership of company securities following the effectiveness of a registration statement.
Summary
- Jonathan H. Kaufman, a director, officer, and 10% owner of Lipella Pharmaceuticals, filed a Form 4 detailing changes in his beneficial ownership.
- The changes occurred on January 15, 2025, following the effectiveness of a registration statement.
- Kaufman's voting power over securities held by Spartan Capital Securities and its affiliates was terminated on this date.
- The securities include Series C Voting Convertible Preferred Stock, common stock issuable upon conversion, and common stock purchase warrants.
- Prior to January 15, 2025, Kaufman held voting power over 303,041 shares of preferred stock, 85,421 warrants expiring on 12/27/2029, and 11,795 warrants expiring on 12/31/2029 through a proxy and power of attorney with Spartan Capital Securities.
- The proxy and power of attorney was terminated upon the registration statement becoming effective.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing, indicating a standard process. The termination of the proxy is a neutral event, and the overall sentiment is neutral to slightly positive due to the formal process being followed.
Positives
- The filing indicates a formal process of registering securities, which is a standard procedure for public companies.
- The termination of the proxy and power of attorney suggests a shift towards more direct ownership and control of securities.
Risks
- The document does not explicitly state any risks, but changes in ownership and control can sometimes lead to uncertainty.
Industry Context
Form 4 filings are a standard part of regulatory compliance for publicly traded companies, providing transparency into the ownership of company securities by insiders.
Comparison to Industry Standards
- Form 4 filings are a common practice for all publicly traded companies in the US, ensuring transparency of insider transactions.
- The specific details of the securities and the proxy arrangement are unique to Lipella Pharmaceuticals and its agreements with Spartan Capital Securities.
Stakeholder Impact
- The filing provides transparency to shareholders regarding insider ownership.
- The termination of the proxy and power of attorney may have a minor impact on the voting dynamics of the company.
Key Dates
| Date | Description |
|---|---|
| 12/20/2024 | Effective date of the irrevocable proxy and power of attorney between the reporting person and Spartan Capital Securities. |
| 12/27/2024 | Expiration date of some of the common stock purchase warrants. |
| 12/31/2024 | Expiration date of some of the common stock purchase warrants. |
| 01/03/2025 | Date of a previous Form 4 filing by the reporting person, which included the Proxy and POA as Exhibit 24. |
| 01/15/2025 | Date of the reported transaction and the effectiveness of the registration statement, which terminated the proxy and power of attorney. |
| 01/17/2025 | Date of the signature on the Form 4. |
Keywords
beneficial ownership, Form 4, Lipella Pharmaceuticals, Jonathan H. Kaufman, securities, proxy, voting power, registration statement, Spartan Capital Securities, preferred stock, common stock, warrants
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.